⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18301156 | 0.98 | — | — | |
| SCHEMBL27873047 | 0.76 | — | — | |
| SCHEMBL3121611 | 0.68 | — | — | |
| SCHEMBL4865079 | 0.67 | — | — | |
| SCHEMBL30372894 | 0.64 | — | — | |
| SCHEMBL3121607 | 0.62 | — | — | |
| SCHEMBL18584269 | 0.61 | — | — | |
| SCHEMBL6888119 | 0.60 | — | — | |
| SCHEMBL5672376 | 0.60 | — | — | |
| SCHEMBL1722456 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115023431-B | Triterpene compounds, pharmaceutical compositions thereof and use thereof in the treatment of diseases mediated by member 1 of the nuclear receptor subfamily 4 | 藤济(厦门)生物医药科技有限公司 | 2024-02-02 | — | — | CN | claimed |
| EP-3781571-B1 | N-[4-OXO-2,3-DIHYDRO-PYRIDO[3,2-B][1,4]OXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOLE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) | HOFFMANN LA ROCHE (CH) | 2024-01-17 | — | — | EP | claimed |
| CN-116648451-A | Antagonist compounds | 阿道尔克斯治疗有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-110023313-B | Bicyclic amide compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-115023431-A | Triterpenoids, pharmaceutical compositions thereof and use thereof in the treatment of diseases mediated by group 4 members of the nuclear receptor subfamily | 藤济(厦门)生物医药科技有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-113332292-A | 6, 7-dihydro-5H-pyrazolo [5,1-b ] [1,3] oxazine-2-carboxamide compounds | 辉瑞公司 | 2021-09-03 | — | — | CN | claimed |
| CN-108699080-B | 6, 7-dihydro-5H-pyrazolo [5,1-b ] [1,3] oxazine-2-carboxamide compounds | 辉瑞公司 | 2021-05-14 | — | — | CN | claimed |
| CN-107922400-B | Muscarinic M1 receptor positive allosteric modulators | 苏文生命科学有限公司 | 2021-05-11 | — | — | CN | claimed |
| WO-2021047672-A1 | TRITERPENOID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING NUCLEAR RECEPTOR SUBFAMILY 4 GROUP MEMBER 1-MEDIATED DISEASE | IXMEDICINE CO., LTD (CN) | 2021-03-18 | — | — | WO | claimed |
| CN-110072863-A | RIP1 kinase inhibitors and methods of use | 豪夫迈·罗氏有限公司 | 2019-07-30 | — | — | CN | claimed |
| CN-108699080-A | 6, 7-dihydro-5H-pyrazolo [5,1-b ] [1,3] oxazine-2-carboxamide compounds | 辉瑞公司 | 2018-10-23 | — | — | CN | claimed |
| EP-1749011-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-29 | — | — | EP | claimed |
| WO-2007064316-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-07 | — | — | WO | claimed |
| EP-1749011-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-07 | — | — | EP | claimed |
| WO-2005118593-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | claimed |
| CN-115427515-B | Resin composition for galvanometer type laser welding, molded article, set for galvanometer type laser welding, in-vehicle camera component, in-vehicle camera module, ultraviolet exposure body, and method for producing molded article | 三菱化学株式会社 | 2024-05-24 | — | — | CN | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| WO-2007062007-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1749011-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005118593-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |